TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Lehen'kyi, V'yacheslav ^a,b   Raphaël, Maylis ^a,b   Oulidi, Agathe ^a,b   Flourakis, Matthieu ^a,b   Khalimonchyk, Sergii ^a,b   Kondratskyi, Artem ^a,b   Gordienko, Dmitri V ^c   Mauroy, Brigitte ^d   Bonnal, Jean Lois ^d   Skryma, Roman ^a,b   Prevarskaya, Natalia ^a,b  

^a Université des Sciences et Technologies de Lille   (France)

^b UNIV LILLE   (France)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CALCITRIOL; CALCIUM; VANILLOID RECEPTOR 6; VANILLOID RECEPTOR;

APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CANCER CELL CULTURE; CANCER GROWTH; CELL COUNT; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

BIOLOGICAL TRANSPORT; CALCITRIOL; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; PROSTATIC NEOPLASMS; TRPV CATION CHANNELS; UP-REGULATION;

EID: 79951834106     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016856     Document Type: Article

References (43)

1. Cooperberg MR, Moul JW, Carroll PR, (2005) The changing face of prostate cancer. J Clin Oncol 23: 8146-8151.
2. Burnstein KL, (2005) Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95: 657-669.
3. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS, (2006) Secondary hormonal therapy for advanced prostate cancer. J Urol 175: 27-34.
4. So A, Gleave M, Hurtado-Col A, Nelson C, (2005) Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23: 1-9.
5. Krishnan AV, Peehl DM, Feldman D, (2003) Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88: 363-371.
6. Lou YR, Qiao S, Talonpoika R, Syvala H, Tuohimaa P, (2004) The role of Vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 92: 317-325.
7. Peehl DM, Feldman D, (2004) Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol 92: 307-315.
8. Vanden Abeele F, Shuba Y, Roudbaraki M, Lemonnier L, Vanoverberghe K, et al. (2003) Store-operated Ca2+ channels in prostate cancer epithelial cells: function, regulation, and role in carcinogenesis. Cell Calcium 33: 357-373.
9. Haverstick DM, Heady TN, Macdonald TL, Gray LS, (2000) Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+ entry. Cancer Res 60: 1002-1008.
10. Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C, et al. (2002) Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 1: 169-179.
11. Skryma R, Mariot P, Bourhis XL, Coppenolle FV, Shuba Y, et al. (2000) Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: involvement in apoptosis. J Physiol 527 (Pt 1): 71-83.
12. Wissenbach U, Niemeyer B, Himmerkus N, Fixemer T, Bonkhoff H, et al. (2004) TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression. Biochem Biophys Res Commun 322: 1359-1363.
13. Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H, (2003) Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 22: 7858-7861.
14. Vanden Abeele F, Lemonnier L, Thebault S, Lepage G, Parys JB, et al. (2004) Two types of store-operated Ca2+ channels with different activation modes and molecular origin in LNCaP human prostate cancer epithelial cells. J Biol Chem 279: 30326-30337.
15. Lehen'kyi V, Flourakis M, Skryma R, Prevarskaya N, (2007) TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways. Oncogene 26: 7380-7385.
16. Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, et al. (2001) CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun 282: 729-734.
17. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, et al. (2005) Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 19: 2685-2695.
18. Krishan A, (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188-193.
19. van Abel M, Hoenderop JG, van der Kemp AW, van Leeuwen JP, Bindels RJ, (2003) Regulation of the epithelial Ca2+ channels in small intestine as studied by quantitative mRNA detection. Am J Physiol Gastrointest Liver Physiol 285: G78-85.
20. Nijenhuis T, Hoenderop JG, Bindels RJ, (2005) TRPV5 and TRPV6 in Ca(2+) (re)absorption: regulating Ca(2+) entry at the gate. Pflugers Arch 451: 181-192.
21. Yamauchi D, Raveendran NN, Pondugula SR, Kampalli SB, Sanneman JD, et al. (2005) Vitamin D upregulates expression of ECaC1 mRNA in semicircular canal. Biochem Biophys Res Commun 331: 1353-1357.
22. Bodding M, Fecher-Trost C, Flockerzi V, (2003) Store-operated Ca2+ current and TRPV6 channels in lymph node prostate cancer cells. J Biol Chem 278: 50872-50879.
23. Zhao XY, Ly LH, Peehl DM, Feldman D, (1997) 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138: 3290-3298.
24. Cheskis B, Lemon BD, Uskokovic M, Lomedico PT, Freedman LP, (1995) Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25-dihydroxyvitamin D3. Mol Endocrinol 9: 1814-1824.
25. Banerjee P, Chatterjee M, (2003) Antiproliferative role of vitamin D and its analogs-a brief overview. Mol Cell Biochem 253: 247-254.
26. Hsieh TY, Ng CY, Mallouh C, Tazaki H, Wu JM, (1996) Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun 223: 141-146.
27. Hsieh T, Wu JM, (1997) Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha,25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 235: 539-544.
28. Eelen G, Verlinden L, van Camp M, van Hummelen P, Marchal K, et al. (2004) The effects of 1alpha,25-dihydroxyvitamin D3 on the expression of DNA replication genes. J Bone Miner Res 19: 133-146.
29. Gniadecki R, (1996) Activation of Raf-mitogen-activated protein kinase signaling pathway by 1,25-dihydroxyvitamin D3 in normal human keratinocytes. J Invest Dermatol 106: 1212-1217.
30. Martin JL, Pattison SL, (2000) Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology 141: 2401-2409.
31. Koh E, Morimoto S, Fukuo K, Itoh K, Hironaka T, et al. (1988) 1,25-Dihydroxyvitamin D3 binds specifically to rat vascular smooth muscle cells and stimulates their proliferation in vitro. Life Sci 42: 215-223.
32. Krohn K, Haffner D, Hugel U, Himmele R, Klaus G, et al. (2003) 1,25(OH)2D3 and dihydrotestosterone interact to regulate proliferation and differentiation of epiphyseal chondrocytes. Calcif Tissue Int 73: 400-410.
33. Buitrago CG, Pardo VG, de Boland AR, Boland R, (2003) Activation of RAF-1 through Ras and protein kinase Calpha mediates 1alpha,25(OH)2-vitamin D3 regulation of the mitogen-activated protein kinase pathway in muscle cells. J Biol Chem 278: 2199-2205.
34. Gniadecki R, (1996) Stimulation versus inhibition of keratinocyte growth by 1,25-Dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol 106: 510-516.
35. Gache C, Berthois Y, Cvitkovic E, Martin PM, Saez S, (1999) Differential regulation of normal and tumoral breast epithelial cell growth by fibroblasts and 1,25-dihydroxyvitamin D3. Breast Cancer Res Treat 55: 29-39.
36. Rashid SF, Mountford JC, Gombart AF, Campbell MJ, (2001) 1alpha,25-dihydroxyvitamin D(3) displays divergent growth effects in both normal and malignant cells. Steroids 66: 433-440.
37. Wiers KM, Lozano Y, Messingham KA, Metz RJ, Young MR, (1997) 1alpha,25-dihydroxyvitamin D3 activates T cells of tumor bearers through protein phosphatase 2A. Cancer Immunol Immunother 44: 97-102.
38. Tischler AS, Powers JF, Downing JC, Riseberg JC, Shahsavari M, et al. (1996) Vitamin D3, lactose, and xylitol stimulate chromaffin cell proliferation in the rat adrenal medulla. Toxicol Appl Pharmacol 140: 115-123.
39. Grauer A, Baier R, Ziegler R, Raue F, (1995) Crucial role of c-myc in 1,25(OH)2D3 control of C-cell-carcinoma proliferation. Biochem Biophys Res Commun 213: 922-927.
40. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942.
41. Banwell CM, Singh R, Stewart PM, Uskokovic MR, Campbell MJ, (2003) Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res 164: 83-98.
42. Gavrilov V, Steiner M, Shany S, (2005) The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res 25: 3425-3429.
43. Swami S, Krishnan AV, Peehl DM, Feldman D, (2005) Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 241: 49-61.